Can Rituximab (Rituxan) cure lymphoma?

Can rituximab cure lymphoma?

Malignant lymphoma was once considered an incurable terminal disease, but with the emergence and development of targeted therapeutic drugs in recent years, this once incurable terminal disease is becoming a potentially curable disease. Rituximab is a monoclonal antibody approved for the clinical treatment of non-Hodgkin's lymphoma. Rituximab combined with CHOP for 8 courses to treat invasive diffuse large B-cell lymphoma can also be combined with CVP to treat indolent follicular lymphoma and treat relapsed or chemotherapy-resistant indolent B-cell non-Hodgkin's lymphoma.

The treatment methods for lymphoma mainly include immunotherapy, chemotherapy, radiotherapy, hematopoietic stem cell transplantation, etc. Among them, immunochemotherapy is considered to be the best first-line treatment option due to its excellent therapeutic effect and good tolerability. A large number of clinical trials have confirmed that 50% of early lymphoma patients can be cured, and half of the patients can still survive healthily after five years. The so-called immunochemotherapy is the use of the biological targeted drug "MabThera" on the basis of traditional chemotherapy, which is an effective method for treating non-Hodgkin's lymphoma. Many international and domestic studies have shown that after immunochemotherapy, the patient's clinical efficacy, disease-free survival time and overall survival are significantly prolonged, making it possible to cure lymphoma.